Stocks and Investing
Stocks and Investing
Fri, September 29, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Danielle Antalffy Initiated (ATRC) at Strong Buy and Held Target at $56 on, Sep 29th, 2023
Danielle Antalffy of UBS, Initiated "AtriCure, Inc." (ATRC) at Strong Buy and Held Target at $56 on, Sep 29th, 2023.
Danielle has made no other calls on ATRC in the last 4 months.
There is 1 other peer that has a rating on ATRC. Out of the 1 peers that are also analyzing ATRC, 0 agree with Danielle's Rating of Hold.
This is the rating of the analyst that currently disagrees with Danielle
- Mike Matson of "Needham" Maintained at Strong Buy with Increased Target to $68 on, Wednesday, July 26th, 2023
Contributing Sources